Arnovie101 / Circunited BioPharma - LARVOL DELTA

In Vivo CD19 Chimeric Antigen Receptor T Cells Show Excellent Safety and Preliminary Efficacy in Refractory Systemic Lupus Erythematosus Treatment (ACR Convergence 2026) - P1 | "In vivo CAR-T generated by Lipid Nanoparticles (LNPs) encapsulating mRNA (mRNA-LNPs) has shown its advantage in the treatment for SLE.Arnovie101 is an engineered CD8+ T cell targeted LNP encapsulating mRNA encoding CD19 CAR...No toxic effects other than fevers less than 39°C were observed which were rapidly recovered after the use of ibuprofen only... These results demonstrate that in vivo CAR-T can be a potential treatment for autoimmune diseases. CAR-T generated by mRNA-LNPs can successfully deplete pathogenic B cells and achieve clinical benefits with minimum side effects."

CAR T-Cell Therapy • Preclinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD8